These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 28280225)

  • 21. Are pretreatment 18F-FDG PET tumor textural features in non-small cell lung cancer associated with response and survival after chemoradiotherapy?
    Cook GJ; Yip C; Siddique M; Goh V; Chicklore S; Roy A; Marsden P; Ahmad S; Landau D
    J Nucl Med; 2013 Jan; 54(1):19-26. PubMed ID: 23204495
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 15-Year Experience of 18F-FDG PET Imaging in Response Assessment and Restaging After Definitive Treatment of Merkel Cell Carcinoma.
    Byrne K; Siva S; Chait L; Callahan J; Bressel M; Seel M; MacManus MP; Hicks RJ
    J Nucl Med; 2015 Sep; 56(9):1328-33. PubMed ID: 26159592
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [(18)F]FDG-PET/CT metabolic parameters as useful prognostic factors in cervical cancer patients treated with chemo-radiotherapy.
    Herrera FG; Breuneval T; Prior JO; Bourhis J; Ozsahin M
    Radiat Oncol; 2016 Mar; 11():43. PubMed ID: 26984385
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 18F-FDG PET for evaluation of the treatment response in patients with gastrointestinal tract lymphomas.
    Kumar R; Xiu Y; Potenta S; Mavi A; Zhuang H; Yu JQ; Dhurairaj T; Dadparvar S; Alavi A
    J Nucl Med; 2004 Nov; 45(11):1796-803. PubMed ID: 15534046
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Value of complete metabolic response by (18)F-fluorodeoxyglucose-positron emission tomography in oesophageal cancer for prediction of pathologic response and survival after preoperative chemoradiotherapy.
    Kim MK; Ryu JS; Kim SB; Ahn JH; Kim SY; Park SI; Kim YH; Song HY; Shin JH; Jung HY; Lee GH; Choi KD; Cho KJ; Kim JH
    Eur J Cancer; 2007 Jun; 43(9):1385-91. PubMed ID: 17512192
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical and prognostic value of 18F-FDG-PET/CT in restaging of pancreatic cancer.
    Albano D; Familiari D; Gentile R; Scalisi S; Midiri F; Messina M; Spada M; Fornito MC; Galia M; Midiri M; Alongi P
    Nucl Med Commun; 2018 Aug; 39(8):741-746. PubMed ID: 29782393
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of tumor response to chemoradiotherapy and predicting prognosis in patients with head and neck squamous cell carcinoma by PERCIST.
    Katsuura T; Kitajima K; Fujiwara M; Terada T; Uwa N; Noguchi K; Doi H; Tamaki Y; Yoshida R; Tsuchitani T; Fujita M; Yamakado K
    Ann Nucl Med; 2018 Aug; 32(7):453-462. PubMed ID: 29858797
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation.
    Qiao W; Zhao J; Wang C; Wang T; Xing Y
    Hematology; 2010 Feb; 15(1):21-7. PubMed ID: 20132658
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Predictive Value of FDG PET/CT for Determining Progression-Free Survival in Advanced Stage III-IV BRAF -Mutated Melanoma Patients Treated With Targeted Therapy-What Can Be Learned From Progression?
    van der Hiel B; Aalbersberg EA; van den Eertwegh AJM; de Wit-van der Veen LJ; Stokkel MPM; Lopez-Yurda M; Boellaard R; Kapiteijn EW; Hospers GAP; Aarts MJB; de Vos FYFL; Boers-Sonderen MJ; van der Veldt AAM; de Groot JWB; Haanen JBAG
    Clin Nucl Med; 2024 Feb; 49(2):138-145. PubMed ID: 38113329
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation.
    Guay C; Lépine M; Verreault J; Bénard F
    J Nucl Med; 2003 Aug; 44(8):1225-31. PubMed ID: 12902411
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anal cancer FDG-PET standard uptake value: correlation with tumor characteristics, treatment response and survival.
    Deantonio L; Milia ME; Cena T; Sacchetti G; Perotti C; Brambilla M; Turri L; Krengli M
    Radiol Med; 2016 Jan; 121(1):54-9. PubMed ID: 26126968
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Negative Predictive Value of NI-RADS Category 2 in the First Posttreatment FDG-PET/CT in Head and Neck Squamous Cell Carcinoma.
    Wangaryattawanich P; Branstetter BF; Hughes M; Clump DA; Heron DE; Rath TJ
    AJNR Am J Neuroradiol; 2018 Oct; 39(10):1884-1888. PubMed ID: 30166429
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prospective Study of Serial Imaging Comparing Fluorodeoxyglucose Positron Emission Tomography (PET) and Fluorothymidine PET During Radical Chemoradiation for Non-Small Cell Lung Cancer: Reduction of Detectable Proliferation Associated With Worse Survival.
    Everitt S; Ball D; Hicks RJ; Callahan J; Plumridge N; Trinh J; Herschtal A; Kron T; Mac Manus M
    Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):947-955. PubMed ID: 29063854
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FDG-PET/CT improves detection of residual disease and reduces the need for examination under anaesthesia in oropharyngeal cancer patients treated with (chemo-)radiation.
    de Ridder M; Gouw ZAR; Navran A; Hamming-Vrieze O; Jasperse B; van den Brekel MWM; Vogel WV; Al-Mamgani A
    Eur Arch Otorhinolaryngol; 2019 May; 276(5):1447-1455. PubMed ID: 30758660
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of FDG PET/CT in the staging and the follow-up of anal carcinoma.
    Vercellino L; Montravers F; de Parades V; Huchet V; Kerrou K; Bauer P; Touboul E; Talbot JN
    Int J Colorectal Dis; 2011 Feb; 26(2):201-10. PubMed ID: 21061012
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 18F-FDG PET for Measurement of Response and Prediction of Outcome to Relapsed or Refractory Mantle Cell Lymphoma Therapy with Bendamustine-Rituximab.
    Lamonica D; Graf DA; Munteanu MC; Czuczman MS
    J Nucl Med; 2017 Jan; 58(1):62-68. PubMed ID: 27469362
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical impact of
    Jung JH; Lee SW; Son SH; Kim CY; Lee CH; Jeong JH; Jeong SY; Ahn BC; Lee J
    Head Neck; 2017 Mar; 39(3):447-455. PubMed ID: 27726225
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy.
    Berthet L; Cochet A; Kanoun S; Berriolo-Riedinger A; Humbert O; Toubeau M; Dygai-Cochet I; Legouge C; Casasnovas O; Brunotte F
    J Nucl Med; 2013 Aug; 54(8):1244-50. PubMed ID: 23674577
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FDG-PET/CT in the evaluation of anal carcinoma.
    Cotter SE; Grigsby PW; Siegel BA; Dehdashti F; Malyapa RS; Fleshman JW; Birnbaum EH; Wang X; Abbey E; Tan B; Kodner IJ; Hunt SR; Lowney JK; Mutch MG; Dietz DW; Myerson RJ
    Int J Radiat Oncol Biol Phys; 2006 Jul; 65(3):720-5. PubMed ID: 16626889
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictive value of (18)F-FDG PET/CT in restaging patients affected by ovarian carcinoma: a multicentre study.
    Caobelli F; Alongi P; Evangelista L; Picchio M; Saladini G; Rensi M; Geatti O; Castello A; Laghai I; Popescu CE; Dolci C; Crivellaro C; Seghezzi S; Kirienko M; De Biasi V; Cocciolillo F; Quartuccio N;
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):404-13. PubMed ID: 26381775
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.